Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Davids, Matthew S. [1 ]
Deng, Jing [1 ]
Ryan, Jeremy [1 ]
Fernandes, Stacey M. [1 ]
Brown, Jennifer R. [1 ]
Letai, Anthony G. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
    Yuan-Fei Shi
    Long Liu
    Ling-Li He
    Jing Ye
    Zhi-Juan Lin
    De-Lin Yuan
    Man-Man Deng
    Zhi-Hong Fang
    Bing Z. Carter
    Bing Xu
    Cell Death & Disease, 11
  • [32] Anti-Leukemia Activity of the BCL-2 INHIBITOR ABT-199 in Pediatric BCP-ALL is Predicted by BCL-2/MCL-1 Expression Indicating Treatment Response
    Seyfried, F.
    Hoerl, R.
    Demir, S.
    Koehrer, S.
    Scheffold, A.
    Stilgenbauer, S.
    Debatin, K-M.
    Meyer, L. H.
    ANNALS OF HEMATOLOGY, 2017, 96 : S79 - S79
  • [33] An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
    Al-Harbi, Sayer
    Hill, Brian T.
    Mazumder, Suparna
    Singh, Kamini
    DeVecchio, Jennifer
    Choudhary, Gaurav
    Rybicki, Lisa A.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Houghton, Janet A.
    Almasan, Alexandru
    BLOOD, 2011, 118 (13) : 3579 - 3590
  • [34] The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
    Sandra Weller
    Astrid Toennießen
    Benjamin Schaefer
    Tobias Beigl
    Alina Muenchow
    Kathrin Böpple
    Ute Hofmann
    Bernhard F. Gillissen
    Walter E. Aulitzky
    Hans-Georg Kopp
    Frank Essmann
    Cell Death Discovery, 8
  • [35] Expression of Bcl-2 pro-survival family proteins predicts pharmacological responses to ABT-199, a novel and selective Bcl-2 antagonist, in multiple myeloma models
    Sampath, Deepak
    Punnoose, Elizabeth
    Beghaert, Erwin
    Belmont, Lisa
    Peale, Franklin
    Nguyen Tan
    Chen, Jun
    Darbonne, Walter
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Fairbrother, Wayne J.
    Souers, Andrew J.
    Elmore, Steven W.
    Leverson, Joel D.
    CANCER RESEARCH, 2013, 73 (08)
  • [36] Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
    Cervantes-Gomez, Fabiola
    Lamothe, Betty
    Woyach, Jennifer A.
    Wierda, William G.
    Keating, Michael J.
    Balakrishnan, Kumudha
    Gandhi, Varsha
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3705 - 3715
  • [37] Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
    Shi, Yuan-Fei
    Liu, Long
    He, Ling-Li
    Ye, Jing
    Lin, Zhi-Juan
    Yuan, De-Lin
    Deng, Man-Man
    Fang, Zhi-Hong
    Carter, Bing Z.
    Xu, Bing
    CELL DEATH & DISEASE, 2020, 11 (07)
  • [38] Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.
    Hogdal, Leah
    Chyla, Brenda
    McKeegan, Evelyn
    Leverson, Joel
    Potluri, Jalaja
    Humerickhouse, Rod
    Mack, Mabry
    DeAngelo, Daniel
    Galinsky, Ilene
    Stone, Richard
    Letai, Anthony
    CLINICAL CANCER RESEARCH, 2015, 21
  • [39] ABT-199, a Selective Small Molecule Inhibitor of Bcl-2, Exhibits Efficacy in Bcl-2 Dependent Malignancies While Sparing Platelets
    Leverson, J.
    Souers, A.
    Boghaert, E.
    Phillips, D.
    Park, C.
    Wendt, M.
    Fairbrother, W.
    Humerickhouse, R.
    Roberts, A.
    Elmore, S.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 23 - 23
  • [40] Bcl-2 and apoptosis in chronic lymphocytic leukemia
    Aaron D. Schimmer
    Irene Munk-Pedersen
    Mark D. Minden
    John C. Reed
    Current Treatment Options in Oncology, 2003, 4 (3) : 211 - 218
12345